Viewpoint: professional integrity in industry-sponsored clinical trials

Area of Science:

• Clinical Research
• Medical Ethics
• Evidence-Based Medicine

Background:

• Evidence-based medicine (EBM) depends on high-quality randomized controlled trials (RCTs).
• Industry-sponsored trials, while common for drug licensing, may present biases that undermine EBM.
• Concerns exist regarding publication bias, selective reporting, and biased interpretation in industry-funded research.

Purpose of the Study:

• To examine the impact of industry sponsorship on the integrity of randomized controlled trials.
• To highlight the ethical implications for physician-investigators and patient well-being.
• To propose solutions for enhancing professionalism and integrity in clinical research.

Main Methods:

• Review of existing evidence on biases in industry-sponsored trials.
• Analysis of the effects of these biases on EBM and physician professionalism.
• Discussion of potential interventions and cultural shifts in academic medicine.

Main Results:

• Industry sponsorship is associated with widespread biases, including publication bias and selective reporting.
• These biases compromise the integrity of clinical trial data used in EBM.
• Physician-investigators' professional integrity and patient well-being may be jeopardized.

Conclusions:

• Regulatory reform alone is insufficient to address biases in industry-sponsored research.
• A cultural shift in academic medicine is needed to reward and recognize physician-investigators who uphold research integrity.
• Educational initiatives promoting integrity in clinical research are recommended.